Gene Therapy Restores Sight

Optogenetic therapy gives limited vision to blind people with retinitis pigmentosa, using special goggles and a single eye injection

Researchers have made a breakthrough in treating blindness, with a gene therapy that can partly restore sight in people with a rare genetic disorder. The approach, known as optogenetic therapy, uses a harmless virus to deliver genetic instructions to nerve cells in the retina, making them light-sensitive.

In a trial involving 10 people with advanced retinitis pigmentosa, six were able to perceive a monochrome image using special goggles that capture and convert images into pulses of light. The therapy was first shown to work in a single blind person in 2021.

Prof Botond Roska, director of the Institute of Molecular and Clinical Ophthalmology Basel, said the concept of optogenetics is valid for vision restoration. He aims to work towards restoring high-resolution vision in the next five to 10 years.

The gene therapy involves a single injection into the eye, which contains a synthetic virus that delivers the genetic instructions for producing a light-sensitive protein. The patients then receive a pair of light-stimulating goggles that capture images and convert them into pulses of light.

Retinitis pigmentosa is a group of genetic disorders that affect over 1.5 million people worldwide, causing progressive death of light-sensitive cells in the eye. However, ganglion cells in the retina deteriorate less quickly, making them a good target for the therapy.

Dr José-Alain Sahel, from the University of Pittsburgh Medical Center, said the therapy is a promising approach for treating blindness. He noted that the technique does not harm the eye and can be used to treat other medical conditions, such as deafness, pain, and epilepsy.

Optogenetics has also shown promise in treating other conditions, including a rare inherited sight condition in dogs. Researchers at Michigan State University found that a single-dose gene therapy treatment can stop blindness from progressing and physically repair damaged connections in the retina.

Key facts

  • Optogenetic therapy can partly restore sight in people with retinitis pigmentosa
  • The therapy uses a harmless virus to deliver genetic instructions to nerve cells in the retina
  • Six out of 10 trial participants were able to perceive a monochrome image using special goggles
  • The therapy aims to restore high-resolution vision in the next five to 10 years

Three perspectives

Neutral

The breakthrough in optogenetic therapy offers new hope for people with rare genetic disorders. While the results are promising, more research is needed to fully understand the potential of the therapy. The next steps will be to refine the technique and expand its application to other conditions.

Positive

The success of optogenetic therapy in restoring limited vision to blind people is a significant milestone in the fight against blindness. The approach has the potential to improve the lives of millions of people worldwide and could lead to new treatments for other medical conditions.

Negative

While the results are promising, the therapy is still in its early stages, and more research is needed to fully understand its potential. The technique is also limited to treating specific genetic disorders, and its application to other conditions is still uncertain.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Four Queenslanders die waiting for ambulances in two weeks
Next storyFour Queenslanders die waiting for ambulances in two weeks

All sections

Edition